Datopotamab Deruxtecan, often abbreviated as DATO, represents a important advancement within targeted cancer treatment. This innovative antibody-drug conjugate pairs the monoclonal antibody specifically directed at HER2 positive expressing cells with the potent chemotherapeutic payload, deruxtecan. The process of action involves the antibody's capa